Paper41246121
Advancing the Therapeutic Frontier in Thyroid Eye Disease.
Mohammadi SO and 1 other. touchREV Endocrinol, 2025. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Advancing the Therapeutic Frontier in Thyroid Eye Disease. Papers, record 41246121. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41246121
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25494967 | Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. | J Clin Endocrinol Metab | 2015 | https://conductscience.org/library/papers/25494967 | PubMed |
| 2 | 35399971 | Thyroid eye disease: From pathogenesis to targeted therapies. | Taiwan J Ophthalmol | 2022 | https://conductscience.org/library/papers/35399971 | PubMed |
| 3 | 40145088 | Targeted immunotherapies for Graves' thyroidal & orbital diseases. | Front Immunol | 2025 | https://conductscience.org/library/papers/40145088 | PubMed |
| 4 | 11834423 | Smoking and thyroid disorders--a meta-analysis. | Eur J Endocrinol | 2002 | https://conductscience.org/library/papers/11834423 | PubMed |
| 5 | 30081019 | Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. | Am J Ophthalmol | 2018 | https://conductscience.org/library/papers/30081019 | PubMed |
| 6 | 39526058 | Teprotumumab's Impact on Proptosis in Long-duration Thyroid Eye Disease: A Systematic Review and Meta-analysis. | touchREV Endocrinol | 2024 | https://conductscience.org/library/papers/39526058 | PubMed |
| 7 | 40156757 | Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress. | BioDrugs | 2025 | https://conductscience.org/library/papers/40156757 | PubMed |
| 8 | 28467880 | Teprotumumab for Thyroid-Associated Ophthalmopathy. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28467880 | PubMed |
| 9 | 26574625 | Atorvastatin reduced soluble receptors of TNF-alpha in systemic lupus erythematosus. | Clin Exp Rheumatol | 2016 | https://conductscience.org/library/papers/26574625 | PubMed |
| 10 | 24967886 | What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review. | Thyroid | 2014 | https://conductscience.org/library/papers/24967886 | PubMed |
| 11 | 34297684 | The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. | Eur J Endocrinol | 2021 | https://conductscience.org/library/papers/34297684 | PubMed |
| 12 | 38374366 | The changing landscape of thyroid eye disease: current clinical advances and future outlook. | Eye (Lond) | 2024 | https://conductscience.org/library/papers/38374366 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42661926 | Cytokines and drugs targeting cytokines in Graves' disease and thyroid eye disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42661926 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41246121
GET https://conductscience.org/api/papers/v1/41246121/authors